ALK and non-small cell lung carcinoma: Therefore, the ESMO (European Society for Medical Oncology) consensus conference on lung cancer and ESMO clinical practice guidelines recommend chemotherapy with platinum doublets as treatment for all stage IV NSCLC patients with epidermal growth factor receptor (EGFR)- and anaplastic lymphoma kinase (ALK)-negative disease [3, 5].